Advertisement

Multivalent Binding and Functional Affinity

  • Fred Karush

Abstract

The evolutionary development of the architecture of the antibody molecule has provided in its contemporary form a distinctive structure superbly suited for multivalent interaction. In addition to multivalence, the general occurrence of multiple and identical antigenic determinants on the surfaces of infectious agents and neoplastic cells has led to the emergence of two further structural features. These, indeed, are required for the effective utilization of the multivalence of antibody. They comprise the property of intramolecular structural symmetry, i.e., identical subunits, resulting in the identity of the antigen-binding sites of the antibody, and the segmental flexibility of the Fab portions of the molecule. The conjunctive effect of these properties is the capacity of the antibody molecule to adjust the separation and relative orientation of its binding sites to the generally fixed distances between the identical complementary groups of the complex ligand. The biological utility of the resulting multivalent interaction is undoubtedly linked to the enhanced affinity which is associated with multivalent binding.

Keywords

Enhancement Factor Association Constant Viral Neutralization Neutralization Reaction Multivalent Interaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blank, S.E., Leslie, G.A., and Clem, L.W., 1972, J. Immunol. 108:665.PubMedGoogle Scholar
  2. Burnet, F.M., Keogh, E.V., and Lusk, D., 1937, Aust. J. Exp. Biol. Med. Sci. 15:226.Google Scholar
  3. Crothers, D.M., and Metzger, H., 1912,Immunochemistry 9:341.CrossRefGoogle Scholar
  4. Eisen, H.N., and Karush, F., 1949, J. Am. Chem. Soc. 71:363.PubMedCrossRefGoogle Scholar
  5. Finkelstein, M.S., and Uhr, J.W., 1966, J. Immunol. 97:565.PubMedGoogle Scholar
  6. Froese, A., and Sehon, A.H., 1965, Immunochemistry 2:135.PubMedCrossRefGoogle Scholar
  7. Gopalakrishnan, P.V., and Karush, F., 1974a, Immunochemistry 11:279.PubMedCrossRefGoogle Scholar
  8. Gopalakrishnan, P.V., and Karush, F., 1974b, J. Immunol. 113:769.PubMedGoogle Scholar
  9. Greenbury, C.L., Moore, D.H., and Nunn, L.A.C., 1965, Immunology 8:420.PubMedGoogle Scholar
  10. Haimovich, J., and Sela, M., 1966, J.Immunol. 103:45.Google Scholar
  11. Hammarström, S., 1973, Scand. J. Immunol. 2:53.PubMedCrossRefGoogle Scholar
  12. Hornick, C.L., and Karush, F., 1969, Isr. J. Med. Sci. 5:163.PubMedGoogle Scholar
  13. Hornick, C.L., and Karush, F., 1972, Immunochemistry 9:325.PubMedCrossRefGoogle Scholar
  14. Jencks, W.P., 1975, Adv. Enzymol. 43:219.PubMedGoogle Scholar
  15. Karush, F., 1962, Adv. Immunol. 2:1.CrossRefGoogle Scholar
  16. Karush, F., 1970, N. Y. Acad. Sci. 169:56.CrossRefGoogle Scholar
  17. Kauzmann, W., 1959, Adv. Protein Chem. 14:1.PubMedCrossRefGoogle Scholar
  18. Klinman, N., 1972, J. Exp. Med. 136:241.PubMedCrossRefGoogle Scholar
  19. Klinman, N.R., Long, C.A., and Karush, F., 1967, J. Immunol. 99:1128.PubMedGoogle Scholar
  20. Mäkelä, O., 1966, Immunology 10:81.PubMedGoogle Scholar
  21. Onoue, I., Tanizahi, N., Yagi, Y., and Pressman, D., 1965, Proc. Soc. Exp. Biol. Med. 120:340.PubMedGoogle Scholar
  22. Schumaker, V.N., Green, G., and Wilder, P.L., 1973, Immunochemistry 10:521.PubMedCrossRefGoogle Scholar
  23. Werner, T.C., Bunting, R., Jr., and Cathou, R.E., 1972, Proc. Natl. Acad. Sci. USA 69:795.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1976

Authors and Affiliations

  • Fred Karush
    • 1
  1. 1.Department of Microbiology School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations